{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:03:23Z","timestamp":1792440203662,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.joca.2021.09.013","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T21:16:34Z","timestamp":1633641394000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Administration of an adeno-associated viral vector expressing interferon-\u03b2 in patients with inflammatory hand arthritis, results of a phase I\/II study"],"prefix":"10.1016","volume":"30","author":[{"given":"J.P.M.","family":"Vrouwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.M.","family":"Meulenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.B.","family":"Klarenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Navas-Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reijnierse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ruiterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bevaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Lamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kloppenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.H.H.","family":"Nelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Burggraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.C.","family":"Kamerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.joca.2021.09.013_bib1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s40273-016-0424-x","article-title":"Economic and humanistic burden of osteoarthritis: a systematic review of large sample studies","volume":"34","author":"Xie","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"10055","key":"10.1016\/j.joca.2021.09.013_bib2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"6937","key":"10.1016\/j.joca.2021.09.013_bib3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/03009742.2015.1060259","article-title":"Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?","volume":"45","author":"Siebuhr","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"10.1016\/j.joca.2021.09.013_bib5","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1529-0131(200012)43:12<2619::AID-ANR1>3.0.CO;2-V","article-title":"The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis","volume":"43","author":"Tak","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-017-1229-9","article-title":"Synovitis in osteoarthritis: current understanding with therapeutic implications","volume":"19","author":"Mathiessen","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.joca.2021.09.013_bib7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.joca.2019.03.007","article-title":"Finger osteoarthritis, change in synovitis is associated with change in pain on a joint-level; a longitudinal magnetic resonance imaging study","volume":"27","author":"van Beest","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40266-015-0330-5","article-title":"Intra-articular therapies in the treatment of hand osteoarthritis: a systematic literature review","volume":"33","author":"Kroon","year":"2016","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","article-title":"Risk profiling for a refractory course of rheumatoid arthritis","volume":"49","author":"Becede","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/hum.2017.181","article-title":"Gene delivery to joints by intra-articular injection","volume":"29","author":"Evans","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.joca.2021.09.013_bib11","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.2741\/1475","article-title":"IFN-beta in rheumatoid arthritis","volume":"9","author":"Tak","year":"2004","journal-title":"Front Biosci"},{"issue":"6","key":"10.1016\/j.joca.2021.09.013_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/ar598","article-title":"Interferon-beta for treatment of rheumatoid arthritis?","volume":"4","author":"van Holten","year":"2002","journal-title":"Arthritis Res"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2003.020347","article-title":"A\u00a0multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.joca.2021.09.013_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ana.410410517","article-title":"Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b","volume":"41","author":"Calabresi","year":"1997","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.joca.2021.09.013_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/ar2457","article-title":"The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis","volume":"10","author":"Brown","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13075-017-1296-y","article-title":"Molecular mechanisms underlying osteoarthritis development: notch and NF-\u03baB","volume":"19","author":"Saito","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.joca.2021.09.013_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"21","key":"10.1016\/j.joca.2021.09.013_bib18","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.joca.2021.09.013_bib20","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013Factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.joca.2021.09.013_bib21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/ard.2004.035063","article-title":"Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy","volume":"64","author":"Adriaansen","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.joca.2021.09.013_bib22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/hum.2005.16.426","article-title":"Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints","volume":"16","author":"Apparailly","year":"2005","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.joca.2021.09.013_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.joca.2021.09.013_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"Mingozzi","year":"2013","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.joca.2021.09.013_bib25","doi-asserted-by":"crossref","first-page":"130612","DOI":"10.1371\/journal.pone.0130612","article-title":"Preclinical potency and biodistribution studies of an AAV 5 vector expressing human interferon-beta (ART-I02) for local treatment of patients with rheumatoid arthritis","volume":"10","author":"Aalbers","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/humc.2015.009","article-title":"Safety, biodistribution, and efficacy of an AAV-5 vector encoding human interferon-beta (ART-I02) delivered via intra-articular injection in rhesus monkeys with collagen-induced arthritis","volume":"26","author":"Bevaart","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"Pt 6","key":"10.1016\/j.joca.2021.09.013_bib27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1099\/vir.0.82603-0","article-title":"Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats","volume":"88","author":"Adriaansen","year":"2007","journal-title":"J\u00a0Gen Virol"},{"issue":"6","key":"10.1016\/j.joca.2021.09.013_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1525-0016(03)00095-9","article-title":"Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6","volume":"7","author":"Grimm","year":"2003","journal-title":"Mol Ther"},{"issue":"18","key":"10.1016\/j.joca.2021.09.013_bib29","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1089\/hum.1998.9.18-2745","article-title":"Novel tools for production and purification of recombinant adenoassociated virus vectors","volume":"9","author":"Grimm","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.joca.2021.09.013_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/ard.2008.089375","article-title":"Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.joca.2021.09.013_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3899\/jrheum.090817","article-title":"Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1\/2 Study","volume":"37","author":"Mease","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.joca.2021.09.013_bib32","first-page":"1401","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0","volume":"34","author":"Woodworth","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.joca.2021.09.013_bib33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.140956","article-title":"Single-joint assessment for the evaluation of intraarticular treatment: responsiveness and discrimination of the composite change index","volume":"42","author":"Aalbers","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.joca.2021.09.013_bib34","first-page":"417","article-title":"The effect of radiation synovectomy in patients with persistent arthritis: a prospective study","volume":"19","author":"Jahangier","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.joca.2021.09.013_bib35","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1136\/ard.2004.031773","article-title":"An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas","volume":"64","author":"Ostergaard","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.joca.2021.09.013_bib36","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3899\/jrheum.140983","article-title":"The longitudinal reliability and responsiveness of the OMERACT hand osteoarthritis magnetic resonance imaging scoring system (HOAMRIS)","volume":"42","author":"Haugen","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/rmdopen-2017-000583","article-title":"Atlas for the OMERACT thumb base osteoarthritis MRI scoring system (TOMS)","volume":"4","author":"Kroon","year":"2018","journal-title":"RMD Open"},{"issue":"21","key":"10.1016\/j.joca.2021.09.013_bib38","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.joca.2021.09.013_bib39","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri3133","article-title":"Immunomodulatory functions of type I interferons","volume":"12","author":"Gonz\u00e1lez-Navajas","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2016.036","article-title":"Empty capsids and macrophage inhibition\/depletion increase rAAV transgene expression in joints of both healthy and arthritic mice","volume":"28","author":"Aalbers","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.joca.2021.09.013_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/humc.2017.249","article-title":"A\u00a0multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients","volume":"29","author":"Kim","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"2","key":"10.1016\/j.joca.2021.09.013_bib43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/art.41142","article-title":"American college of rheumatology\/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee","volume":"72","author":"Kolasinski","year":"2019","journal-title":"Arthritis Rheum"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458421009304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458421009304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:55:02Z","timestamp":1761018902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458421009304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1063458421009304"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2021.09.013","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration of an adeno-associated viral vector expressing interferon-\u03b2 in patients with inflammatory hand arthritis, results of a phase I\/II study","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.","name":"copyright","label":"Copyright"}]}}